Trial Profile
Induction Chemotherapy Followed by Cetuximab Plus Definitive Radiotherapy Versus Radiation Plus Cisplatin
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Sep 2023
Price :
$35
*
At a glance
- Drugs Cetuximab (Primary) ; Cisplatin; Docetaxel; Fluorouracil
- Indications Head and neck cancer; Squamous cell cancer
- Focus Therapeutic Use
- Acronyms INTERCEPTOR
- 18 Aug 2023 Status changed from active, no longer recruiting to completed according to results published in the Oral Oncology.
- 18 Aug 2023 Results assessing prognostic impact of sarcopenia on overall survival (OS) and progression free survival (PFS) in HNSCC patients undergoing chemoradiation therapy within a prospective clinical trial of chemoradiation vs induction chemotherapy followed by radiation and cetuximab published in the Oral Oncology
- 27 Feb 2017 Planned number of patients changed from 278 to 282.